Market capitalization | €1.53b |
Enterprise Value | €-2.02b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 3.85 |
EV/Sales (TTM) EV/Sales | -3.72 |
P/S ratio (TTM) P/S ratio | 2.81 |
P/B ratio (TTM) P/B ratio | 0.53 |
Revenue growth (TTM) Revenue growth | -5.75% |
Revenue (TTM) Revenue | €543.97m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
14 Analysts have issued a Galapagos forecast:
14 Analysts have issued a Galapagos forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 212 212 |
197%
197%
|
|
Depreciation and Amortization | 36 36 |
20%
20%
|
|
Stock Compensation | 57 57 |
36%
36%
|
|
Operating Cash Flow | -391 -391 |
21%
21%
|
|
Investments | 19 19 |
48%
48%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -410 -410 |
22%
22%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Head office | Belgium |
CEO | Paulus Stoffels |
Employees | 1,123 |
Founded | 1999 |
Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.